All In Biotech

Drug Trial Radar · NCT04990037

A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma

A Phase 1b Dose Escalation and Expansion Study of CAN04, a Monoclonal Antibody Targeting IL1RAP, in Combination With Modified FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma

Last checked: Nov 20, 2026Latest source record: Jun 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

25

Actual

Start

Jul 19, 2021

Primary completion

May 30, 2023

Study completion Jun 15, 2023

Sponsor

Lead sponsor
Cantargia ABIndustry
Sponsor type
Industry
First posted
Aug 4, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will consider the safety and effectiveness of a study drug, CAN04, in combination with FOLFIRINOX, in the treatment of metastatic pancreatic ductal adenocarcinoma.

Conditions

  • Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

  • CAN04Drug

    Administered intravenously

  • FOLFIRINOXDrug

    Administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of TEAEs (Treatment-emergent adverse events)Time frame: From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.
  2. Number of participants with DTLs (dose-limiting toxicities)Time frame: Up to day 28
  3. Number of subjects with 1 or more TEAEs leading to dose modificationsTime frame: From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.
  4. Number of subjects with grade ≥ 3 TEAEsTime frame: From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.
  5. Percentage of subjects with grade ≥ 3 TEAEsTime frame: From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.
  6. Number of subjects with 1 or more TEAEs leading to treatment discontinuationTime frame: From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.
  7. Percentage of subjects with 1 or more TEAEs leading to dose modificationTime frame: From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.
  8. Percentage of subjects with 1 or more TEAEs leading to treatment discontinuationTime frame: From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.
  9. Number of subjects with 1 or more SAEs (serious adverse events)Time frame: From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.
  10. Percentage of subjects with 1 or more SAEsTime frame: From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.

Locations

9 sites in 2 countries. Site status is shown where the registry gives one.

  • EDOG - Institut Bergonie - PPDS

    Bordeaux, France

  • EDOG Institut de Cancerologie de l'Ouest - PPDS

    Nantes, France

  • EDOG - Centre Eugene Marquis Centre Regional de Lutte Contre Le Cancer - PPDS

    Rennes, France

  • Institut de Cancerologie de l'Ouest

    Saint-Herblain, France

  • Instituto de Investigacion Oncologica Vall d'Hebron (VHIO) - EPON

    Barcelona, Spain

  • ICO l'Hospitalet - Hospital Duran i Reynals

    Barcelona, Spain

  • Hospital General Universitario Gregorio Maranon

    Madrid, Spain

  • START MADRID_Hospital Universitario Fundacion Jimenez Diaz

    Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.